Compare CYTK & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | MBLY |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.3B |
| IPO Year | 2004 | 2022 |
| Metric | CYTK | MBLY |
|---|---|---|
| Price | $68.45 | $11.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $77.87 | $19.29 |
| AVG Volume (30 Days) | 1.9M | ★ 4.1M |
| Earning Date | 11-05-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $87,211,000.00 | ★ $1,938,000,000.00 |
| Revenue This Year | $363.61 | $15.48 |
| Revenue Next Year | $64.33 | $7.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2609.26 | 7.61 |
| 52 Week Low | $29.31 | $10.74 |
| 52 Week High | $69.33 | $22.51 |
| Indicator | CYTK | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 42.15 |
| Support Level | $59.85 | $10.93 |
| Resistance Level | $67.98 | $12.54 |
| Average True Range (ATR) | 2.72 | 0.44 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 91.35 | 45.34 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.